珠海润都制药股份有限公司 2024 年度独立董事述职报告（TANWEN） 本人 TANWEN，作为珠海润都制药股份有限公司（以下简称"公司"）的独立 董事，2024 年度严格按照《中华人民共和国公司法》（以下简称"《公司法》"） 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号 —主板上市公司规范运作》以及《公司章程》《独立董事工作制度》等有关规定， 诚实守信、勤勉尽职地履行独立董事职责。 在 2024 年度中，本人及时关注公司的经营及发展情况，积极出席公司 2024 年度相关会议，认真审议各项议案，并对相关事项发表意见，维护全体股东特别 是广大中小股东的合法利益等方面，独立、负责、诚信、谨慎地履行了职责。现 将 2024 年度任职期内履行职责的情况报告如下： 一、独立董事的基本情况 （一）个人基本情况 TANWEN:1956年出生，美国籍，博士，教授、博士生导师，美国内布拉斯加 大学医学中心博士、美国哈佛大学医学院博士后、美国哥伦比亚大学医学院副研 究员。曾任华南理工大学生命科学院院长、广东工业大学生物医药研究院院长。 曾获世界卫生组织研究学者奖；美国心脏学会及哈佛大学研究学者奖； ...

根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监 管指引第1号——主板上市公司规范运作》等要求，珠海润都制药股份有限公司 （以下简称"公司"）董事会，就公司在任独立董事TANWEN先生、王波先生、 叶建木先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事TANWEN先生、王波先生、叶建木先生的任职经历以及签署 的相关自查文件，公司董事会认为上述人员未在公司担任除独立董事以外的任 何职务，也未在公司的主要股东公司担任任何职务，与公司以及主要股东之间 不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响 独立董事独立性的情况。公司独立董事符合《上市公司独立董事管理办法》《 深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》中对 独立董事独立性的相关要求。 珠海润都制药股份有限公司 董事会 2025年04月29日 珠海润都制药股份有限公司董事会 关于独立董事独立性情况的专项意见 ...

珠海润都制药股份有限公司 一、独立董事的基本情况 （一）个人基本情况 2024 年度独立董事述职报告（叶建木） 本人叶建木，自 2023 年 3 月 14 日起任第五届董事会独立董事，并分别任董 事会审计委员会主任委员、董事会薪酬与考核委员会委员。在职期间，本人充分 运用专业知识及多年的工作经验，并严格按照《中华人民共和国公司法》（以下 简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公 司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、法规、规章 的规定和要求，诚实、勤勉、独立地履行职责，积极出席公司相关会议，认真审 议董事会及专门委员会的各项议案，对公司重大事项发表了独立意见，充分发挥 了独立董事及各专业委员会的作用。现就本人 2024 年度履行独立董事职责情况 汇报如下： 2024年度，公司共召开4次董事会会议，本人均亲自出席，并对公司董事会 会议审议的相关议案全部投了赞成票。 （二）列席股东大会会议情况 2024年度，公司共召开3次股东大会，本人2次亲自列席，1次通讯参会。 （三）出席董 ...

Financial Performance - The company's revenue for 2024 was CNY 1,182,362,768.46, representing a decrease of 8.48% compared to CNY 1,291,887,142.06 in 2023[18]. - Net profit attributable to shareholders for 2024 was CNY 39,883,176.39, down 40.38% from CNY 66,898,617.98 in 2023[18]. - Basic earnings per share decreased by 40.00% to CNY 0.12 in 2024, down from CNY 0.20 in 2023[18]. - Total assets at the end of 2024 were CNY 2,193,636,977.65, a decrease of 1.53% from CNY 2,227,773,648.98 at the end of 2023[18]. - The company reported a weighted average return on equity of 3.22% for 2024, down from 5.23% in 2023[18]. - The company achieved total operating revenue of 1,182,362,768.46 CNY in 2024, a decrease of 8.48% year-on-year[69]. - The net profit attributable to shareholders was 3,988.32 CNY, down 40.38% compared to the previous year[69]. - The revenue from chemical drug formulation manufacturing was 683,286,133.88 CNY, accounting for 57.79% of total revenue, with a year-on-year decline of 12.92%[72]. - The revenue from raw material drug manufacturing was 493,544,661.78 CNY, representing 41.74% of total revenue, with a slight decrease of 0.72%[72]. - The company's total liabilities included a significant amount of restricted assets, totaling ¥261,870,353.19 at year-end[91]. Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares to all shareholders, based on a total of 334,893,286 shares[4]. - A cash dividend of 1.5 CNY per 10 shares (before tax) is proposed, amounting to a total cash dividend of 50,233,992.90 CNY, which represents 100% of the profit distribution[157]. - The company has no plans for stock dividends or capital reserve transfers to increase share capital, with all remaining undistributed profits carried forward to the next fiscal year[157]. - The total distributable profit for the fiscal year 2024 is based on the lower of the consolidated and parent company reports, which is 493,128,906.74 CNY[156]. Operational Highlights - The net cash flow from operating activities increased by 22.30% to CNY 211,187,476.03 in 2024, compared to CNY 172,679,270.44 in 2023[18]. - The company has not reported any changes in its main business since its listing[17]. - The company has established a comprehensive quality management system throughout the drug lifecycle, enhancing product competitiveness and reputation in the market[35]. - The company has established a comprehensive product matrix covering various therapeutic areas, with innovative micro-pellet formulations showing unique advantages in chronic disease treatment[46]. - The company has established a complete production and operational asset system, ensuring no asset encroachment by controlling shareholders[114]. Research and Development - The company is focusing on developing 13 cardiovascular drugs and various other therapeutic categories in 2025[83]. - The company has achieved significant progress in R&D, with multiple products like 瑞加诺生 and 美阿沙坦钾 receiving domestic and international registration approvals, expanding the product line[81]. - The company’s R&D investment amounted to 131.27 million yuan, supporting the advancement of several innovative projects, with a focus on clinical value and innovation[59]. - A total of 58 patent applications were submitted during the reporting period, with 33 patents granted, including 7 invention patents[60]. - The company has built a technical platform for high-tech drug development, enhancing its capabilities in CMO and CDMO services[62]. Market Expansion - The company is actively expanding its market presence in emerging markets such as the Middle East, South Asia, Southeast Asia, and South America, while maintaining long-term strategic partnerships with major domestic and international manufacturers[38]. - The company is actively pursuing international business in formulations, leveraging its global production platform[102]. - The company has been recognized as one of the top 100 Chinese chemical pharmaceutical companies in 2023 and has been included in the 2024 Guangdong Province Green Manufacturing List[28]. Environmental Compliance - The company strictly adheres to environmental protection policies, ensuring wastewater and air emissions meet regulatory standards[167]. - The company has installed online monitoring equipment at major discharge points to ensure real-time compliance with environmental regulations[169]. - The company achieved compliance with the stricter standards for wastewater discharge as per the Guangdong provincial regulations[168]. - The company’s hazardous waste management complies with national regulations, ensuring safe handling and disposal[171]. - The company has established an environmental management system since 2014 and received ISO 14001 certification in 2017, ensuring continuous improvement in environmental practices[199]. Governance and Management - The company has established a governance framework that ensures compliance with relevant laws and regulations, enhancing decision-making and internal control effectiveness[111]. - The company has a robust governance structure that complies with legal and regulatory requirements[112]. - The management team includes professionals with diverse backgrounds, enhancing the company's strategic capabilities in the pharmaceutical sector[126]. - The company has engaged in multiple investor communications to discuss business development, including meetings and online interactions throughout 2024[104][106][108]. - The company has implemented a "Quality and Return Dual Improvement" action plan to enhance operational quality and shareholder returns[109].

Financial Performance - The company's revenue for Q1 2025 was ¥254,703,072.24, a decrease of 16.79% compared to ¥306,093,972.60 in the same period last year[5] - Net profit attributable to shareholders was ¥1,868,170.85, down 93.57% from ¥29,055,820.54 year-on-year[5] - The basic and diluted earnings per share dropped by 88.89% to ¥0.01 from ¥0.09 in the same period last year[5] - The company experienced a 90.46% decline in total profit, which amounted to ¥3,200,157.00 compared to ¥33,527,966.43 in the previous year, primarily due to policy impacts on formulation products[8] - Total comprehensive income attributable to the parent company was CNY 1,868,113.62, a decrease from CNY 29,056,328.01 in the previous period[18] - Net profit fell to ¥1.87 million compared to ¥29.06 million in the previous period, a decline of approximately 93.5%[17] Cash Flow and Liquidity - The net cash flow from operating activities increased by 4.93% to ¥23,916,914.54, compared to ¥22,794,035.25 in the previous year[5] - Cash inflow from operating activities totaled CNY 301,796,623.37, while cash outflow was CNY 277,879,708.83, resulting in a net cash inflow[18] - Cash flow from investing activities was negative at CNY -4,540,594.19, compared to CNY -55,794,033.20 in the previous period[19] - Cash inflow from financing activities was CNY 48,000,000.00, while cash outflow was CNY 69,460,930.77, leading to a net cash outflow of CNY -21,460,930.77[19] - The ending balance of cash and cash equivalents was CNY 175,573,870.47, down from CNY 196,412,733.73 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,187,546,987.06, a slight decrease of 0.28% from ¥2,193,636,977.65 at the end of the previous year[5] - Total liabilities decreased to ¥1.03 billion from ¥1.04 billion, a decline of about 0.9%[15] - Current liabilities totaled ¥496.36 million, down from ¥524.16 million, a decrease of approximately 5.3%[15] - Long-term borrowings increased to ¥382.46 million from ¥361.67 million, an increase of about 5.2% year-over-year[15] - The company reported a significant increase in expected liabilities by 39.76% to ¥2,637,715.68 due to increased provisions for hazardous waste costs[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,629[10] - The total number of shares held by the top two shareholders, Li Xi and Chen Xinmin, is 100,865,992 shares each, accounting for 60.24% of the total share capital at the end of the reporting period[11] - The top 10 shareholders include various institutional investors, with the largest being Li Xi and Chen Xinmin, both holding 30.12% each[11] - The company has a significant pledge situation, with Li Xi pledging 80,521,385 shares, which is approximately 79.8% of his total holdings[11] - There are no significant changes in the financing and securities lending activities of the top shareholders reported[11] Operational Metrics - Total operating revenue decreased to ¥254.70 million from ¥306.09 million, a decline of approximately 16.8% year-over-year[16] - Total operating costs reduced to ¥249.33 million from ¥273.58 million, reflecting a decrease of about 8.8% year-over-year[16] - Research and development expenses increased to ¥27.50 million from ¥24.95 million, representing an increase of about 10.2% year-over-year[16] - Total current assets increased to ¥905,332,383.62 from ¥885,753,509.84, showing a growth of about 2.93%[13] - Accounts receivable decreased from ¥138,011,657.35 to ¥132,542,849.01, indicating a reduction of about 3.39%[13] - Inventory rose to ¥455,508,538.34 from ¥442,008,841.36, representing an increase of approximately 3.05%[13] Future Outlook and Reporting - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[20] - The first quarter report was not audited, indicating preliminary financial results[20] - The company has not disclosed any new product developments or technological advancements during the reporting period[12] - The company has not reported any mergers or acquisitions in the current financial period[12]

证券代码：002923 证券简称：润都股份 公告编号：2025-009 珠海润都制药股份有限公司 关于变更经营范围并完成工商登记的公告 特此公告。 珠海润都制药股份有限公司 董事会 2025年04月25日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"）于 2025 年 03 月 28 日召开 第五届董事会第十一次会议，于 2025 年 04 月 15 日召开 2025 年第一次临时股东 大会，审议通过了《关于变更经营范围并修订<公司章程>的议案》。具体内容详 见公司于 2025 年 03 月 29 日、2025 年 04 月 16 日刊登于指定信息披露媒体上的 相关公告。 公司于近日完成了经营范围变更和《公司章程》备案手续。经工商登记机关 最终核准，公司变更前后的经营范围如下： | 变更前 | 变更后 | | --- | --- | | 许可项目：药品生产；药品批发；药 | 许可项目：药品生产；药品批发；药品 | | 品零售；危险化学品经营；药品进出口； | 零售；危险化学品经营；药品进出口；药品 | | 药品委托 ...

证券代码：002923 证券简称：润都股份 公告编号：2025-008 珠海润都制药股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开情况 珠海润都制药股份有限公司（以下简称"公司"）于2025年03月29日在公司指定 信息披露媒体《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯 网（www.cninfo.com.cn）上披露了《珠海润都制药股份有限公司关于召开2025年第 一次临时股东大会的通知》（公告编号：2025-004），公司定于2025年04月15日以现 场投票与网络投票相结合的方式召开2025年第一次临时股东大会。 1、召开时间：2025年04月15日（星期二）14:30； 2、召开地点：珠海市金湾区三灶镇机场北路6号公司会议室； 4、召集人：本次会议由公司董事会召集； 5、主持人：公司董事长陈新民先生因工作原因不能出席现场会议，经半数以上 董事共同推选，本次股东大会 ...

广东广信君达律师事务所 关于 珠海润都制药股份有限公司 2025 年第一次临时股东会的 法律意见书 二〇二五年四月 地址：广东省广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 29 层、10 层、11 层（01-04 单元、10-11 单元） 邮编（P.C）：510623 电话（Tel）：020-37181333 传真（Fax）：020-37181388 网址（Website）：www.etrlawfirm.com 法律意见书 广东广信君达律师事务所 关于珠海润都制药股份有限公司 2025 年第一次临时股东会的法律意见书 （（2025）粤广信君达律委字第 1378-1 号 致：珠海润都制药股份有限公司 广东广信君达律师事务所（（以下简称"本所"）接受珠海润都制药股份有限公 司（（以下简称"公司"）的委托，指派律师（（以下简称"本所律师"）出席公司 2025 年第一次临时股东会（（以下简称"本次股东会"），并获授权依据（ 中华人民共和 国公司法》（以下简称（ 公司法》）、（ 中华人民共和国证券法》 上市公司股 东会规则》和（ 珠海润都制药股份有限公司章程》（以下简称（ 公司章程》）的 有关规定出具本法律 ...

珠海润都制药股份有限公司 章 程 第一章 总 则 | 第一章 | 总 | 则 2 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | 股 | 份 3 | | 第一节 | | 股份发行 3 | | 第二节 | | 股份增减和回购 4 | | 第三节 | | 股份转让 5 | | 第四章 | | 股东和股东大会 6 | | 第一节 | | 股东 6 | | 第二节 | | 股东大会的一般规定 8 | | 第三节 | | 股东大会的召集 11 | | 第四节 | | 股东大会的提案与通知 12 | | 第五节 | | 股东大会的召开 13 | | 第六节 | | 股东大会的表决和决议 16 | | 第五章 | | 董事会 21 | | 第一节 | | 董事 21 | | 第二节 | | 董事会 24 | | 第三节 | | 董事会专门委员会 29 | | 第六章 | | 总经理及其他高级管理人员 31 | | 第七章 | | 监事会 33 | | 第一节 | | 监事 33 | | 第二节 | | 监事会 33 | | 第八章 | | 财务会计制度、利润分配和审计 ...